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Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant disease of the 
myocardium characterized by left ventricular hypertrophy and myofibrillar disarray. 
HCM is considered the most common cause of sudden cardiac death in young athletes. 
Mutations of the myosin-binding protein C (cMyBP-C) have been targeted as one of the 
most prevalent causes of this disease, and the deactivating effects of such mutant forms 
on the quality control ubiquitin-proteasome system (UPS) contribute to cardiac 
dysfunction. The E334K mutant cMyBP-C has been shown to destabilize its protein and 
lead to the impairment of the UPS, resulting in the clinical arrhythmias and cardiac 
dysfunction observed in HCM patients. A case study has been incorporated to illustrate 
the clinical manifestations of apical hypertrophic cardiomyopathy (ApHCM). ApHCM is 
a rare morphological variant of HCM characterized by nonobstructive hypertrophy 
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Overview of Disease 
Introduction 
 HCM is a disease characterized by the enlargement of cardiac muscle cells that 
causes thickening of the myocardium. Thickened heart muscle can reduce the efficiency 
of cardiac function by obstructing blood flow, decreasing ejection fraction, causing mitral 
valve regurgitation, and disrupting the electrical signals throughout the heart (1). HCM is 
an inherited disease most widely caused by mutations in sarcomeric proteins which 
function in heart muscle contraction (2). Severity of the symptoms associated with HCM 
are highly variable as some people show no signs or health issues related to the disease 
while others present arrhythmias, obstructed blood flow, and heart failure (3). As a 
common cause of sudden cardiac arrest in young people and the leading cause of heart-
related sudden death in young adults, HCM and the molecular mechanisms by which it is 
caused present a highly investigated topic of current research (4). This review presents a 
comprehensive overview of the clinical and genetic characteristics, diagnosis, and 
treatment of HCM, as well as an inspection of current studies, theories, and therapeutic 
targets related to the pathogenesis of this disease.  
 
Clinical Features 
 The main feature of HCM is an excessive thickening of the heart muscle, or 
myocardium. Hypertrophy of the myocardium can occur evenly throughout the left 
ventricle, a condition classified as concentric HCM. More commonly seen is asymmetric 
HCM, which is the thickening at the septum, or the muscular wall that separates the left 
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and right chambers of the heart (5). Thickening is seen in ventricular septal measurement, 
which can range anywhere from 1.3−6.0+ cm as compared to the normal range of 
0.08−1.2 cm (4). Both types of HCM cause a narrowing that can block or reduce blood 
flowing out from the left ventricle to the aorta, a condition called “outflow tract 
obstruction” (5). In order to overcome this narrowing or blockage, as well as compensate 
for the reduced end-diastolic volume and ejection fraction of the heart caused by the 
thickening and stiffness of the left ventricle, the heart must pump harder to deliver 
sufficient amounts of oxygen-rich blood to the rest of the body. This increased force 
results in higher blood pressure and other health issues observed in this disease. The 
narrowing of the left ventricle can also disrupt the proper function of the mitral valve, as 
it can strike the thickened septum and cause blood to leak back into the left atrium (5). 
Another prominent feature of HCM is the cellular changes observed in cardiac cells, 
which not only enlarge, but also undergo organizational changes to assume irregular 
conformations in a condition referred to as myocardial disarray (5). This disarray disrupts 
the normal patterns of electrical signaling throughout the heart and causes various types 
of abnormal heart rhythms, or arrhythmias (6).  
 
Pathophysiology 
 The molecular events that lead to the clinical phenotype of HCM are unclear, 
although several potential pathways have been proposed and investigated. Impaired 
myofibrillar contractile function due to genetic mutations encoding sarcomeric proteins 
accounts for the hypertrophy and diastolic dysfunction in many HCM cases (7). Other 
suggested mechanisms include altered energy homeostasis, changes in calcium cycling 
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and sensitivity, and increased myocardial fibrosis (7). As the sarcomere is responsible for 
generating and transmitting contractile forces of the heart, mutations in sarcomeric 
proteins which disrupt normal sarcomeric function can cause inefficient energy utilization 
(7). This inefficient energy usage compromises the ability of cardiomyocytes to maintain 
critical homeostatic functions, which can result in ion imbalances and consequent 
arrhythmias (7). Cardiac arrhythmogenesis is also regulated by specific channel proteins 
whose level of expression is regulated by quality control systems within the cell such as 
the ubiquitin proteasome system (UPS) (8). The impairment of the UPS can cause 
accumulation of cardiac channel proteins and thus changes in intracellular ion 
concentrations. Perturbation of calcium fluxes resulting from either increase in ion 
channel expression or accumulation in Ca2+ handling proteins can cause significant 
increases in calcium transients and longer action potential durations (APD), which are 
features observed in HCM cases (7,8). The activation and proliferation of fibroblasts is 
also observed in HCM patients and is correlated with impairment of cardiac relaxation 
(7). Although the connection between HCM-associated sarcomeric mutations and this 
proliferation of nonmyocytes has yet to be elucidated, increased expression in profibrotic 




 The symptoms and onset of HCM is case dependent, as there is no particular 
symptom or period of occurrence unique to the disease (4). The severity of manifestation 
of HCM ranges from almost no health-related problems to the development of life-
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shortening heart conditions such as sudden cardiac arrest, or sudden cardiac death (5). 
Sudden cardiac death, most commonly caused by ventricular fibrillation, is among the 
most devastating consequences of HCM and has the highest occurrence in preadolescent 
and adolescent youth, especially during extreme exertion (6). However, most people 
diagnosed with HCM are at low risk of sudden cardiac death and present, to varying 
degrees, numerous symptoms associated with ventricular tachycardia (fast but regular 
heart rhythm) and heart failure, which is defined as weaker than normal contractile forces 
of the heart (3,5,6). The most commonly presented of these symptoms is dyspnea, or 
shortness of breath, which is caused by elevated diastolic pressure that reverts back into 
pulmonary circulation (6). Elevated pressure gradients across the left ventricular outflow 
tract also can result in dizziness, which is exacerbated by high levels of exertion (6). 
Another cause of dizziness, as well as the cause of palpitations experienced by HCM 
patients is arrhythmias, such as sinus pauses, atrial fibrillation, atrial flutter, 
supraventricular tachycardia, and premature atrial and ventricular beats (6).  Also 
common is syncope, or fainting or passing out, which results from arrhythmias or 
inadequate cardiac output upon exertion (6). Syncope is more commonly seen in children 
and young adults having reduced left ventricular chamber size due to hypertrophy (6). 
Presyncope can also be experienced by HCM patients and is characterized by “greying-
out” spells which can be relieved upon lying down (6). Both syncope and presyncope are 
indications of patients who present high risk of sudden death (6). Angina, or chest pain, 
may also occur due to subendocardial ischemia resulting from ventricular hypertrophy 
(6). A less common symptom of HCM is congestive heart failure, which can also result 
from subendocardial ischemia or diastolic dysfunction (6).  
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Epidemiology 
 HCM is estimated to affect one in every 500 Americans and is considered most 
prevalent in young adults, serving as the leading cause of sudden cardiac death in people 
under 30 (5). Most HCM-related sudden cardiovascular deaths occur in adolescents and 
young adults, especially competitive athletes, and the risk of sudden death in children is 
as high as 6% per year (6). However, expression of HCM is not confined to young adults 
and athletes, as cases of HCM have been observed in people of all ages (1). HCM most 
commonly presents in the second or third decade of life, and the average age for 
diagnosis is 35 (4,9). This disease has not been correlated to any specific trends, yet some 
studies suggest that HCM may be slightly more prevalent in males (9). According to the 
echocardiographic analysis of one study conducted by the Coronary Artery Risk 
Development in (Young) Adults (CARDIA) Study, prevalence of HCM in men and 
women was 0.26:0.09% and in blacks to whites was 0.24:0.10% (10). However, no 
widely accepted ethnic or gender trends have been reported as unique to HCM.  
 
Genetics 
 HCM is the most common form of Mendelian–inherited heart disease and is 
transmitted as an autosomal-dominant trait with incomplete penetrance in the majority of 
cases (2,7). Fifty percent of HCM cases can be attributed to specific disease-causing 
mutations, although it is still a rather heterogeneous disease, with the most common 
forms being linked to more than 500 mutations on 19 different genes encoding 
sarcomeric proteins (2). For three quarters of all clinical cases of HCM, the underlying 
mutation has been identified as alterations in either of the two genes MYH7 and 
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MYBPC3, which encode β-myosin heavy chain and cardiac myosin-binding protein C, 
respectively (2,7). In contrast, the third most predominant gene mutation occurring in 
HCM cases is on the gene encoding cardiac troponin T (TNNT2), which accounts for less 
than 10% of HCM cases (7). MYBPC3 presents a popular target of investigation in 
current research, as at least 185 HCM-associated mutations have been identified on this 
protein (2). Although these include several missense mutations, approximately 61% of 
known MYBPC3 mutations are nonsense or frameshift mutations, which can in many 
cases cause premature termination in the transcription of mRNA and thus produce C-
terminal truncated MYBPC’s lacking binding sites essential for proper function (2). 
HCM patients are generally heterozygotes, and the high rate of phenotypic variability 
suggests the presence of other factors and disease modifiers such as environment, gene 
polymorphisms, posttranslational modification, and epigenetics as having an influence on 
the penetrance of this disease (2). Due to the heterogeneity of HCM and the number of 
unidentified gene mutations and regulatory DNA sequences associated with the disease, 
genetic testing for HCM presents clear limitations in diagnostic methods and clinical 
utility (7). Furthermore, in regards to the HCM-associated mutations that have been 
identified, the pathogenic pathways by which these mutations cause the disease remain 
largely unclear and controversial (7).   
 
Diagnosis 
 HCM may first be suspected upon presentation of symptoms, detection of a heart 
murmur, or an abnormal electrocardiogram (ECG/EKG) (1,4). An ECG records electrical 
signals from the heart and can detect abnormal electrophysiology due to heart thickening 
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and myocardial disarray (4). However, in a minority of cases, an ECG of HCM patient 
may be normal, or ECG abnormalities can be attributed to other heart conditions (1). For 
this reason, an echocardiogram (ECHO) is currently used as a more conclusive method to 
diagnose HCM. An echocardiogram uses sound waves to produce an image of the heart 
in order to examine muscle thickness, movement, and blood flow, and thus identify 
abnormalities in the heart muscle and valves (1). Types of echocardiograms include 
transthoracic echocardiograms, in which an ultrasound beam is aimed through one’s chest 
to the heart, and transesophageal echocardiograms, in which a flexible transducer is 
guided into one’s esophagus in order to obtain a more detailed image of the heart (1). In 
cases where echocardiogram images are inconclusive, cardiac magnetic resonance 
imaging (MRI) is performed to produce higher resolution images of the heart by use of 
magnetic fields and radio waves (4). In order to record and detect abnormal heart rhythms 
over an extended period of time, a holter monitor is used and functions as a portable ECG 
that records a continuous electrocardiogram of the heart over the course of one to two 
days (1). Other effects of HCM, such as high blood pressure inside the heart can be 
measured using various techniques including cardiac catheterization, in which a catheter 
is threaded into heart chambers through which dye is injected in order to produce 
angiograms of the heart and blood vessels (1). Screening for HCM through these multiple 
methods is recommended regularly for people with first-degree relatives with HCM (1). 
An ECG or ECHO should be given each year to such people until they reach adulthood 
and stop competitive athletics, after which time screening can be conducted less 
frequently (1).  
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Treatment 
 In order to relieve symptoms and prevent sudden cardiac death of those at risk, 
various treatment options including drugs, surgery and other methods to destroy 
obstructive heart tissue or regulate heart rhythms are offered. Current drug treatment 
includes various medications selected to relax the heart and allow it to pump more 
efficiently. Such drugs commonly prescribed include: beta blockers, such as atenolol or 
metoprolol used to relieve chest pain and palpitation; calcium channel blockers, such as 
verapamil which improves filling of the heart and lowers heart rate and blood pressure; 
and anti-arrhythmic drugs, such as Amiodarone and Disopyramide used when arrhythmia 
is detected (4). Specific complications may require the use of the following additional 
drugs: anticoagulants for patients with persistent atrial fibrillation, diuretics for 
development of fluid retention, and antibiotics in cases in which there is an increased risk 
of bacterial infection (1). In cases in which medication does not relieve symptoms, 
surgical options are next considered. Such surgical options include septal myectomy, in 
which a portion of the thickened, overgrown septum is removed in order to improve 
blood flow and reduce mitral valve regurgitation (4). Also available is septal ablation, or 
septal alcohol ablation, by which portions of thickened myocardium are destroyed by 
alcohol injection through a catheter. However, this presents potential disruption of the 
heart’s electrical system, which would then require implantation of a pacemaker (1).  A 
pacemaker is a small electronic device that is inserted beneath the skin and sends constant 
electrical signals to the heart to regulate heartbeat. A similar device also used to monitor 
one’s heartbeat is a implantable cardiodiverter-defibrillator (ICD) (1). This device is 
capable of sensing potentially lethal arrhythmias and inducing electrical shocks to 
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terminate such arrhythmias and restore normal heart rhythm. ICD implantation is offered 
to patients identified as being high risk for sudden cardiac death (4). Pulmonary vein 
ablation or pulmonary vein antrum isolation (PVAI) is also offered as an alternative 
treatment for atrial fibrillation for those with HCM and disconnects pathways of 
abnormal rhythms in impulse firing pulmonary veins by ablation (4).  
 
Body of Review 
 Although mutations encoding sarcomeric proteins have been determined as the 
most prevalent cause of HCM, over 500 such mutations in 19 different sarcomeric genes 
have been identified in typical forms of HCM, and the exact pathogenesis of this 
heterogeneous disease remains unclear (2).  However, most of these mutations have been 
located in or associated with the function of the MYH7 and MYBPC3 genes, which 
encode β-myosin heavy chain and cardiac myosin-binding protein C (cMyBP-C), 
respectively (2). cMyBP-C is a component of the thick filaments of the sarcomere, and 
mutations in this protein are widely recognized as causes of HCM (2). Specific 
mechanisms by which MYBP3 mutations cause the disease are controversial and 
extensively investigated in current clinical studies. One proposed molecular mechanism 
involves the hypothesized effects of carboxyl terminal truncated cMyBP-C proteins and 
there altered accumulation and/or incorporation into the sarcomere (11). Studies such as 
those conducted by Flavigny et al., in which localization of several different 
immunolabeled COOH-truncated cMyBP-C proteins is observed in the A-band of the 
sarcomere suggest that truncated MYBPC3 mutations are incorporated into the sarcomere 
and act as poison polypeptides that disrupt myofibrillar architecture and result in altered 
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contractility and other symptoms of HCM (11). A different mechanism, such as that 
proposed by Mathias Gruen and Mathias Guatel attributes disruption in the regulatory 
function of MyBP-C to interactions with β-myosin S2 mutations (12). cMyBP-C is 
positioned transversely in the A-band of the sarcomere and interacts with the myosin rod 
at the S2 fragment to regulate contractility and maintain structural integrity of the 
sarcomere by phosphorylation (12). Thus, familial hypertrophic cardiomyopathy 
representative mutations in β-myosin S2 may alter interactions with cMyBP-C and result 
in complications associated with this disease (12).  
 In addition to impaired myofibrillar contractile function, MYBPC3 mutations 
have also been suggested to influence the cardiac arrhythmogenesis commonly seen in 
HCM. Being that the generation and transduction of electrical signals throughout the 
heart is affected by ion flux within cardiomyocytes, ion channel proteins play an integral 
role in regulating cardiac arrhythmogenesis (8). As ion channel protein levels are in turn 
regulated by the ubiquitin-proteasome system (UPS), impairment of this system by 
mutant forms of cMyBP-C such as E334K can result in accumulation of cardiac channel 
proteins and lead to electrophysiological dysfunction (8). Accumulation of other proteins 
including calcium handling proteins and pro-apoptotic proteins is also caused by the 
suppression of the UPS by unstable E334K mutant cMyBP-C (8). This effect results in a 
higher concentration of calcium transients associated with cardiac apoptosis, which can 
be attenuated by treatment with calcium antagonist azelnidipine (8). Other potential 
treatments include cMyBP-C replacement by gene therapy and suppression of 
endogenous mutation at pre-mRNA levels (8). Although RNA-targeting therapies could 
be well suited for treating HCM, further development of analytical techniques to better 
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 Hypertrophic cardiomyopathy is a very common cardiac disorder that exhibits 
remarkable clinical and genetic heterogeneity. The severity of symptoms characteristic of 
this disease can range from little to no expression, to sudden cardiovascular death. 
Diagnostic tests are used to reveal thickening of the heart muscle, irregular blood flow, 
and abnormal electrical signals, and treatment involves removal of overgrown 
myocardium or implantation of a pacemaker or defibrillator. The spectrum of genes that 
are involved in the development of HCM has expanded, but the most predominant of 
these genes are those that encode cMy-BPC. Studies of genetically engineered models of 
mutants of such genes have increased the understanding of some potential mechanisms of 
the pathophysiology of this disease, although much still remains unclear. The current 
repertoire of identified HCM genes has allowed gene-based diagnosis, and further 
investigation of specific mechanisms of such genes, such as the impairment of the 
ubiquitin-proteasome system for example, will lead to therapeutic targets and provide 
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Literature Review:  
Quality control ubiquitin-proteasome system impairment by E334K mutant cMyBP-C 
instability is associated with hypertrophic cardiomyopathy 
 
Introduction 
 cMyBP-C mutations are of the most common genetic causes associated with HCM 
(8). cMyBP-C is a component of the thick filaments of the sarcomere and regulation of 
cMyBP-C by phosphorylation may alter thick filament structure and affect thick-thin 
filament interaction (13). cMyBP-C is therefore a key regulator of contraction and 
relaxation of the heart, yet mechanisms by which mutations in the MYBPC3 gene 
encoding cMyBP-C lead to HCM remain elusive. However, Western blot analysis has 
consistently shown significantly lower levels of C-terminal truncated and other mutant 
cMyBP-C proteins compared to wild type expression levels, suggesting that mutant 
proteins are instable and qualitatively degraded by some quality control mechanism 
within the cell (14). The three potential quality control systems that regulate expression 
of cMyBP-C mutations include nonsense-mediated mRNA decay (NMD), UPS, and 
autophagy (2).  Impairment of the UPS caused by the instability of the missense 
MYBPC3 mutation E334K may contribute to accumulation of both ion channels and Ca2+ 
handling proteins and play an important role in the progression of cardiac dysfunction 
(8). The hypothesized proteasome inhibition by E334K cMyBP-C has been investigated 
by measuring the expression levels and effects of proteins that accumulate as a result of 
impaired degradation through the UPS.  Such proteins include pro-apoptotic proteins and 
other cardiac ion channel and Ca2+ handling proteins; the overexpression of which can 
lead to prolongation of action potential duration (APD), elevated intracellular Ca2+ 
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concentration, and cardiac cell death. These effects are closely associated with the 
arrhythmias and electrophysiological dysfunctions characteristic of HCM (1).  
 
Results  
UPS impairment associated with E334K mutant cMyBP-C protein expression 
Different mutations identified in Japanese HCM patients using denaturing HPLC 
and sequencing were investigated in COS-7 and neonatal rat cardiac myocytes (NRCM) 
in a study conducted by Bahrudin et al. Expression of five novel MYBPC3 mutations 
including E334K were identified and protein stability and proteasome activity in cells 
expressing such mutations were examined through various affinity chromatography 
techniques. Western blot analysis of protein extracts from COS-7 cells co-transfected for 
48hr with selected mutant MYBPC3 and enhanced green fluorescent protein (EGFP) 
plasmids was performed. Figure 1a depicts a Western blot and quantitative densitrometric 
scan of target myc-MyBP-Cs. This procedure and analysis was duplicated for COS-7 
cells co-transfected with either wild-type (Wt) or E334K and EGFP constructs in absence 
or after treatment with MG132 (Fig. 1b), a proteasome inhibitor. Expression of E334K 
mutant protein was observed to be remarkably reduced in COS-7 cells in comparison to 
Wt cMyBP-C protein. E334K mutant protein levels were seen to increase by pretreatment 

















Figure 1. cMYBP-C protein levels in COS-7 cells. (a) Western blot analysis (left) of 
protein extracts of COS-7 cells co-transfected with MYBPC3 and EGFP plasmid; right, 
quantitative densitrometric scan of corresponding blot. (b)Representative Western blot 
(top) and densitrometric scan (bottom) of protein extracts pretreated with MG132. 
Quantification of EGFP was used to control minor differences in transfection efficiency 
and β-actin served as a control for protein loading. Figure adapted from reference 3. 
 
 Stability of the E334K mutant cMyBP-C protein was investigated by measuring 
the rate of its degradation within COS-7 expressing cells using pulse-chain analysis. Wt 
and E334K cMyBP-C transfected COS-7 cells were pulse-labeled with [35S]methionine, 
and the cMyBP-C protein density was determined at specific time intervals by use of 
anti-myc immunoprecipitates subjected to autoradiography. Decay curves constructed 
from representative autoradiographs such as the one displayed in Figure 2 reveal the fast 
degradation process of E334K mutant cMyBP-C protein. From the analysis conducted by 
Bahrudin et al. represented in Figure 2, the half-life of E334K mutant protein was 
observed to be 2.01 ± 0.26 h, which is significantly faster than the half-life of the Wt 
(9.55 ± 2.059 h). The other cMyBP-C mutants were observed to have the same half-life 
as that of the Wt. Pretreatment with MG132 was found to prolong the half-life of E334K 
mutant protein to 10.46 ± 2.68 h (3). Additional correlative analysis from 
(a) (b) 
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immunoprecipitation experiments shows that the polyubiquitination, which targets 
proteins for the proteolytic process of the UPS, of E334K mutant protein is significantly 

















E334K is a missense mutation in MYBPC3 caused by an amino acid charge 
change of +2, as the positively charged lysine (K) is substituted for the negatively 
charged glutamic acid (E) at position 334. Affects on the stability of the cMyBP-C 
protein were investigated by substituting differently charged amino acids at position 334 
and measuring protein expression with anti-myc immunoprecipitates in Western blot 
analysis. Stability of the protein was restored by replacement of glutamic acid (E) with 
aspartic acid (D), another negatively charged amino acid. However, replacement with 
uncharged glutamine (Q) and nonpolar glycine (G) only partially restored the expression 
level of the protein (Fig. 3a) (3). Position 334 is located in exon 12, which encodes the 
MyBP-C motif, a phosphorylation dependent regulatory region that controls actin and 
Fig. 2. Degradation and half-life 
determination of E334K mutant 
cMyBP-C protein. Wt and 
E334K mutant protein 
expressing COS-7 cells pulse-
labeled with [35S]methionine 
and chased at indicated time 
increments. The anti-myc 
immunoprecipitates were 
detected using autoradiography. 
The autoradiograph (top) and 
corresponding decay curve 
(bottom) are shown. Figure 
adapted from reference 3.  
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myosin-S2 binding and thus contraction and relaxation of cardiac muscle (2). 
Phosphorylation of E334K compared to Wt cMyBP-C in transfected COS-7 cells was 
examined by immunoblotting with anti-phosphoserine or anti-myc antibody to measure 
phosphorylated E334K mutant cMyBP-C protein compared to the Wt (Fig. 3b). There 
was no observed difference in phosphorylation between E334K mutant and Wt cMyBP-C 













Fig. 3. Protein stability and phosphorylation of missense mutation at position 334 of 
cMyBP-C.  (a) COS-7 cells were co-transfected with Wt, E334K, and three other 
constructs encoding cMyBP-C with different charged amino acids at position 334 
(E334D, E334Q, and E334G) for 48 h and protein extracts were used for Western 
blotting (left) and densitrometric scanning (right). Minor differences in transfection 
efficiency were controlled for by the use of EGFP, and β-actin was used as the control for 
protein loading. (b) Cell lysates from cells transfected with either Wt or E334K mutant 
were blotted with anti-myc immunoprecipitates and subjected to anti-phosphoserine or 
(b) 
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anti-myc antibody. Representative blots (left) and quantitative densitrometric scan (right) 
are shown. Figure adapted from reference 3.  
 
Impairment of UPS associated with expression of unstable E334K mutant 
cMyBP-C protein was determined by measuring the 20S proteasome (the core catalytic 
unit within the UPS) activity from purified proteasomes isolated either from Wt or 
mutant cMyBP-C transfectants of COS-7 cells. Proteasome or chymotrypsin-like activity 
was indicated by the detection of fluorescence of free 7-amino-4-methylcoumarin (AMC) 
produced from specific digestion of substrate peptide. From this analysis, as shown in 
Figure 4a, reduced proteasome 20S activity was observed in E334K expressing cells as 
compared to Wt. To further investigate proteasome activity, levels of pro and anti-
apoptotic proteins were measured in either Wt or E334K mutant cMyBP-C stable 
transfectants of COS-7 cells (Fig. 4b). Western blot analysis with anti-myc and other 
antibodies for the chosen pro or anti-apoptotic proteins detected the corresponding 
protein levels and revealed greater accumulation of pro-apoptotic proteins in E334K 












Fig. 4. Impaired proteasome 
activity associated with 
expression of E334K mutant 
cMyBP-C protein. (a) 20S 
proteasome activity in isolated 
proteasomes of Wt or cMyBP-
C mutant transfectants of 
COS-7 cells measured by 
fluorescence detection of free 
7-amino-4-methylcoumarin 
(AMC) liberated from 
digestion of substrate peptide 
Suc-Leu-Leu-Val-Tyr-AMC. 
(b) Western blot analysis of 
pro and anti-apoptotic 
proteins in Wt or E334K 
expressing COS-7 cells (left) 
and quantitative 
densitrometric scan (right) are 
shown.  Figure adapted from 
reference 3.  
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Accumulation of cardiac proteins caused by suppressed UPS activity  
 
Studies such as those conducted by Bahrudin et al. further investigate suppressed 
proteasome activity and the implications of UPS impairment using cardiomyocytes from 
a HL-1 cardiac muscle cell line and primary cultured NRCMs. Levels of specific proteins 
as well as the electrophysiological activity of these cell models overexpressing either Wt 
of E334K cMyBP-C were analyzed using immunoprecipitation and electrophysiological 
recording techniques. Lower cMyBP-C protein levels, higher levels of polyubiquitination 
of these proteins, and suppressed chymotrypsin-like activity observed in E334K 
expressing COS-7 cells presented in Figures 1 and 4 were confirmed through similar 
experiments using HL-1 cells. Further experimentation led to the discovery of suppressed 
trypsin-like and caspase-like activities in E334K expressing HL-1 cells and NRCMs. 
Consequences of such impaired proteasome activity were explored by measuring 
resulting levels of ion channel proteins and Ca2+ handling proteins. Expression levels of 
such proteins, including Kv1.5, Nav1.5, Cav3.2, Hcn4, Cav1.2, Serca, RyR2, and Ncx 
were measured in NRCM and HL-1 cells expressing either Wt or E334K cMyBP-C (Fig. 
5a). Significantly increased levels of these proteins in E334K expressing cardiac cells 
compared to cells expressing the Wt protein were observed, while no such trend was 
observed in the mRNA levels of these proteins in E334K and Wt cardiac cells. Chase 
experiments revealed the prolonged decay of these ion channels proteins and Ca2+ 
handling proteins in E334K expressing cells compared to the decay of such proteins in 
the Wt (Fig. 5b). Despite higher levels and prolonged decay of these proteins, Western 
blot analysis of accumulated Kv1.5 and Cav1.2 showed localization of these channel 
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proteins in the cell membrane, indicating that these proteins do not become sequestered in 




































 Fig. 5. Accumulation of cardiac channel and calcium handling proteins in E334K 
expressing cells. (a) Western blot analysis using β-actin as a control for protein loading 
(left), quantitative densitrometric scan (middle), and quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) with mRNAs of indicated proteins in E334K and 
Wt cells are shown. (b) Chase analysis of ion channel proteins at the indicated time 
(a) 
(b) (c) 
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intervals after treatment with transcription inhibitor cycloheximide with representative 
blots (left) and time-course decays (right) are shown. (c) Quantitative densitrometric scan 
of representative blot (not shown) of cytosolic and membrane fractions of Kv1.5 and 
Cav1.2 in E334K and Wt expressing HL-1 cells. Na+/K+ ATPase and tubulin from whole-
cell lysates were used as protein marker and loading control. Figure adapted from 
reference 1.  
 
 The electrophysiological effects of ion channel and Ca2+ handling protein 
accumulation in cardiac cells were investigated by examining the action potential 
duration (APD) and calcium transients in E334K and Wt expressing HL-1 cells. Using 
the whole-cell patch-clamp technique, the APD of isolated HL-1 cells was measured. 
Figure 6a shows the increase in APD at 90% repolarization of HL-1 cells expressing 
E334K compared to the Wt. Furthermore, some E334K mutant expressing HL-1 cells 
exhibited afterdepolarizations (ADs), which are abnormal depolarizations that may 
interrupt the phases of the cardiac action potential.  Calcium transients in HL-1 cells were 
also recorded by exciting E334K mutant or Wt MYBPC3 and pMAX-EGFP 
cotransfected cells at 365 ± 10 nm and recording fluorescence images at 405 ± 10 nm and 
480 ± 10 nm every 10 ms. After subtracting background fluorescence, the ratios of these 
images were calculated and used to determine resting and peak levels as well as 
amplitudes of calcium transients (Fig. 6b). Such measurement levels were observed to be 














Fig. 6. Action potential and calcium transients in cardiomyocytes expressing E334K 
cMyBPC. (a) (i) Traces of the action potential of HL-1 cells expressing either E334K or 
Wt cMyBPC (top) and the bar graph representing the APD of those cells (bottom) are 
shown. (ii) Presence of ADs in E334K expressing HL-1 cells was traced (top) and 
quantified in a bar graph (bottom). (b) Representative traces of calcium transients were 
measured in both Wt and E334K expressing HL-1 cells (top), and the component resting 
Ca2+ levels, peak Ca2+ levels, and Ca2+ amplitudes were quantified in bar graphs 
(bottom). Figure adapted from reference 1.  
 Intracellular calcium concentration serves an important role in regulating the 
electrophysiological function of cardiomyocytes and has been linked to specific cell 
death modalities (17). Calcium transients and APDs, as well as apoptosis regulating 
protein levels associated with  E334K mutant protein were further investigated by 
examining the effects of the Ca2+antagonist, azelnidipine. By pretreating both Wt and 
E334K NRCMs and HL-1 cells with 1 µM azelnidipine for 24 hours and then measuring 
the calcium transients and APDs as described in Figure 6, azelnidipine was observed to 
both lower calcium transients (Fig. 7a) and shorten APD (Fig. 7b) in both cell models to 
levels and duration times comparable to Wt expressing cells. Immunoprecipitation of 
proteins within Wt and E334K cells showed a decrease in ratio of pro-apoptotic to anti-
apoptotic proteins when the cardiac cells were treated with azelnidipine (Fig. 7c), which 
(a) 
(b) 
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results in a decrease in the prevalence of cardiac cell death. Additional chase and 
immunofluorescence experiments showed that azelnidipine neither affected the time-
dependent decay of E334K mutant proteins nor affected the accumulation of the mutant 
protein or it’s incorporation into the sarcomere, as indicated by the punctuate florescence 
observed in both the E334K expressing cells and the E334K expressing cells treated with 
















Fig. 7. Effects of azelnidipine on E334K cMyBPC protein. (a) Normalization of calcium 
transients in E334K expressing HL-1 cells treated with azelnidipine indicated by the 
representative traces (top) and bar graphs (bottom) of rest, peak, and amplitude calcium 
transients. (b) Decrease in APD of azelnidipine treated E334K expressing HL-1 cells 
shown by the action potential traces (left) and corresponding bar graph of APD (right). 
(c) Western blot analysis (left) and bar graph (right) showing levels of indicated pro and 
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presence and absence of azelnidipine treatment. (d) Immunofluorescence of either Wt or 
E334K mutant cMyBPC in NCRMs with and without azelnidipine treatment. Arrows 
indicate punctuate fluorescence that possibly correlates to E334K protein accumulation. 





 Evidence for UPS impairment by mutant cMyBP-C proteins has been documented in 
various studies. The stability of cMyBP-C protein is amino acid charge dependent (Fig. 
3) and the E334K missense mutation has been found to cause instability of cMyBP-C. 
The phosphorylative function of the MyBP-C motif of the cMyBP-C protein encoded for 
at position 334 is unaffected in the E334K mutant form and the protein structure of this 
mutant is unknown. However, control of mutant E334K expression by UPS is indicated 
by reduced levels of E334K mutant protein in transfected COS-7 cells and the restored 
expression of this mutant by treatment with proteasome inhibitor MG132 (Fig. 1). The 
significantly shorter half-life and higher level of polyubiquination observed in E334K 
mutant as compared to the Wt also suggest the instability of E334K mutant and its 
degradation by UPS (Fig. 2). As a consequence of its encounter with instable E334K 
mutant cMyBP-C, the UPS is impaired. UPS impairment is evinced by the lesser 
concentration of peptides resultant of 20S proteasome activity in E334K expressing cells 
than in Wt expressing cells (Fig. 4) (3). Lower trypsin-like and caspase-like activities 
observed in HL-1 and NRCMS expressing E334K also indicate suppressed proteasome 
activity (1). Such reduced proteasome activity results in accumulation of proteins 
including ion channel and Ca2+ handling proteins, yet proper localization of these 
accumulated proteins within the membrane is retained (Fig. 5). The accumulation and 
prolonged decay of these proteins in E334K expressing NRCMs and HL-1 cells may 
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account for the higher peaks and amplitudes of Ca2+ transients observed in these cell 
models. Increased concentration of intracellular Ca2+ may in turn account for the 
prolonged APDs and presence of ADs observed in E334K expressing cells (Fig. 6). ADs 
in E334K mutant cMyBP-C expressing cells resulting from prolonged APDs and 
increased Ca2+ transients may cause arrhythmias in cardiac myocytes (1). Furthermore, 
increased ratios of pro-apoptotic to anti-apoptotic proteins and thus increased cell 
apoptosis in E334K mutant expressing HL-1 and COS-7 cells were observed (Fig. 4).  
Apoptosis of cardio myocytes related to suppressed proteasome activity and increased 
intracellular Ca2+ is observed in failing hearts and has been postulated to result in fibrosis 
and consequent arrhythmias (1). This theorized effect as well as observed influences of 
UPS impairment by instable E334K mutant protein are diagrammed in Figure 8. Taken 
together, prolongation of APDs, occurrence of ADs,  higher calcium transients, and 
enhanced apoptosis observed in E334K mutant cMyBP-C transfected cardiomyocytes are  
all abnormalities observed in left ventricular hypertrophy and thus these 
electrophysiological effects of E334K expression serve as possible explanations for the  











Fig. 8. Proposed mechanisms for electrophysiological dysfunction associated with UPS 
impairment by E334K cMyBP-C expression.  Figure taken from reference 1.  
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The Ca2+ antagonist azelnidipine was found to suppress Ca2+ transients and attenuate 
the apoptosis of cardiac myocytes expressing E334K cMyBP-C (Fig. 7). This finding 
suggests the presence of a mechanism of increased apoptosis related to increased 
intracellular Ca2+, and  effects of azelnidipine in normalizing elevated intracellular 
Ca2+and APD serves as a potential treatment in abating cardiac apoptosis. However, Ca2+ 
antagonist azelnidipine affects neither the degradation of E334K cMyBP-C nor its 
incorporation or accumulation into the sarcomere, and thus UPS impairment by instable 
E334K and consequent apoptosis may still persist (3). Potential apoptotic models, such as 
the mitochondrial death pathway induced by sarcoplasmic reticulum Ca2+ overload, as 
well as pathways dependent on proteasome inhibition and enhancer-binding proteins such 
as C/EBP homologous protein have been hypothesized, yet further studies to investigate 
these possibilities are required (18,19).  Furthermore, it was found that substitution of 
glutamic acid for differently charged residues at position 334 corresponds to instability of 
cMyBP-C, yet lack of information on the crystal structure of E334K mutant cMyBP-C 
hinders further analysis of the effect of E334K mutation on its protein structure and 
function. Determination of the structure of mutant E334K and the way in which it is 
incorporated into the sarcomere, as well as the specific mechanism by which it impairs 
the UPS warrants further investigation (3). Additional perspectives report the importance 
of β-adrenergic receptors (β-ARs) in the cardiac dysfunction of HCM associated with 
cMyBP-C mutations. Studies have shown that overactivity of β-ARs leads to suppressed 
signaling by increased activity of inhibitory G protein,  which negatively affects growth 
and function of cardiac myocytes. Evidence of increased β-adrenergic signaling in 
cardiomyocytes of patients with chronic heart failure has been presented, yet 
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understanding this possible link between β-ARs, UPS impairment by E334K mutant 
cMyBP-C, and HCM calls for further experimentation and analysis (20). Ultimately, 
elucidation of the precise structure and pathophysiology of this E334K mutant cMyBP-C 
presents possible therapeutic targets invaluable for treating the clinical arrhythmias and 
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Clinical Case Study 
The following case study concerns an otherwise healthy, partially vaccinated 19-
year-old, Japanese American female who was referred to a cardiologist upon presenting 
an abnormal EKG performed for a sports physical. The purpose of this case study is to 
investigate this patient’s cardiac function and elucidate the cause of her 
electrophysiological dysfunction.  
 
Addie Mori  
Chief Complaint 
 Addie Mori is a 19-year-old, Japanese American female. Upon presenting an 
abnormal pre-participation EKG for sports at UNR, Addie was brought to the hospital the 
following day for further evaluation.  
History of Present Illness 
 Addie had never had an EKG done prior to this physical exam. She has never 
experienced any chest pain, discomfort, or heart palpitations to prompt such procedure. 
She has had syncope 3 times within the past 5 years, all occurring shortly after moderate 
exercise. She reports waking up after each episode and feeling perfectly normal. She 
otherwise doesn’t feel limited in any way.  
Past Medical History 
 Addie was born overseas on a U.S. base. After receiving three rounds (2, 4 and 6 
month) of vaccinations, her mother opted to not vaccinate her any further. Addie 
contracted pertussis at 4 months old and a series of ear infections after her mother 
stopped breast-feeding her around 20 months old.  Beyond having her adenoids removed 
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at the age of 2 and her wisdom teeth removed at the age of 17, Addie has had no other 
surgeries or hospitalizations. Addie has had regularly occurring headaches throughout her 
youth, which her mother attributes to her forceps facilitated birth. When Addie began to 
participate in organized sports in her early teen years, she would on occasion complain of 
shortness of breath. She was tested for exercise-induced asthma with negative results.  
Social History 
 Addie is an active adolescent and has participated in sports throughout middle 
school and high school. Addie played a semester of collegiate soccer last fall and then 
transferred to UNR this spring. She was receiving a physical to try out for the UNR 
soccer team when her abnormal EKG was detected. Addie follows a considerably healthy 
diet and reports no known food allergies. She has temporarily adopted a vegan diet within 
the last month for a school assignment. Addie is well liked by her peers and teammates, 
excels in academics, and leads a balanced life. She denies the use of any drugs or alcohol 
and is currently not on any medications. Addie has a boyfriend of a couple weeks but 
states to be sexually inactive at the present. 
Family History 
 Addie’s mother is very active with no medical problems at age 51. Her father is 
age 52 and has a record of abnormal EKGs. He states to have an enlarged left ventricle 
and has been told to have an “athletic heart.” Reports from 2010 shows left ventricular 
wall thickness of 1.3cm, yet he has refused further investigative procedures. Addie’s 
father denies ever passing out and only experiences shortness of breath and minor chest 
discomfort on occasion. Both of Addie’s paternal grandparents had bypass surgery. 
Addie’s little sister was born with a benign pediatric heart murmur of which she grew out 
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by the age of five. Her other little sister presents no symptoms of abnormal cardiac 
function. There is no history of early or sudden cardiac death.  
 
Review of Systems 
  
General: Maintains an average body weight. Sleeps well and reports sufficient and 
sustained energy throughout daily activities. Minor fatigue due to strenuous exercise.  
HEENT: Reports recent vision problems such as trouble seeing the white board in class. 
Regular dull headaches. No auditory problems or oral lesions. Last dental visit within the 
past year.  
Pulmonary: Occasional shortness of breath during exercise as stated in PMH.  
Cardiac: No notable chest pain. See HPI.  
Gastro: No nausea, indigestion, or difficulty swallowing. Reports regular stools. 
Heme.: No bruising or hemorrhaging. Mother suspects anemia due to lack of red meat in 
diet. 
Endo.: Denies mood swings. No symptoms of thyroid problems. 
Musculoskeletal: Post workout stiffness. No joint swelling. Minor pain in right ankle 
from former sprain.  
Neuro.: Dizziness before syncope. See HPI.  
Derm.: No rashes or lesions. Minimal acne.  
Uro/Genito.: No past UTI’s or irritative/obstructive symptoms. Regular light 
menstruation every month. LMP: 4/16/14. Sexually inactive.   
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Physical Exam 
 
BP 110/73 | Pulse 52 |  O2 100% |  Ht 5’5” (165.1 cm) | Wt  141lb (63.957kg) |  BMI  
23.46kg/m2 
 
CONSTITUTIONAL: She is oriented to person, place, and time and moves all 
extremities. She has no acute distress and is not agitated, anxious, or depressed. She 
appears well-developed and well-nourished.  
HEAD: Normocephalic and atraumatic.  
EYES: Cojunctivae are normal and clear, PERRLA 
THROAT: No gross abnormalities in oral mucosa, palate or teeth, MMM 
NECK: FROM. Supple. Shows no venous distension. Full active range of motion. 
Thyroid is normal size. No carotid bruit.  
CARDIOVASCULAR: Slightly slower rate, regular rhythm and normal S1 and S2 
sounds. Exam reveals no gallop and no friction rub. No murmur heard. Radial and pedal 
pulses bilaterally 2+. No cyanosis. Cap refill less than 2 sec. No peripheral edema. No 
JVD. Non-displaced PMI.  
PULMONARY/CHEST: Effort normal and BS normal. No crackles or wheezes. No 
accessory muscle use.  
ABDOMINAL: Soft. Bowel sounds are normal. Exhibits no distension. No 
organomegaly, masses, or tenderness.  
MUSCULOSKELETAL: Full active range of motion. Exhibits no edema or no 
tenderness. Normal muscle strength with no kyphoscoliosis.  
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GU: Deferred.  
BREASTS: Deferred.  
NEUROLOGICAL: A/O x3. Speech clear, appropriate, and cooperative. Cranial nerves 
2-12 fully intact. Sensation intact. Gait is normal. No focal neurological deficit.  
SKIN: Warm and dry with no dermatitis or xanthomas.  
 






Figure 9: 12-lead EKG of patient- Sinus Bradycardia. Biphasic morphology of P wave 
indicates left atrial hypertrophy. Positive deflections of leads I and aVF indicate normal 
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axis alignment. Increased QRS amplitude in V5 suggests left ventricular hypertrophy. 
Deep anterolateral T-wave inversion reveals abnormal left ventricular repolarization.  













Figure 10: 2-D echocardiogram of patient- Mild LVH with wall thickness of 1.5 cm mid 
apical septum. Normal left ventricular end-diastolic dimension of 4.1cm (normal 
<5.5cm). LA enlargement with LA volume of 40 ml/m2 (normal <28ml/m2).  Mild mitral 
regurgitation. Image obtained from Yusuf SW, Bathina JD, Banchs J, Mouhayar EN, 
Daher IN. Apical hypertrophic cardiomyopathy. World J. Cardiol. [Internet]. 2011 Jul 26 
[cited 2014 Apr 24];3(7):256–9. (22) 
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Laboratory Panels:  
 
CBC                    Standard Range             Values   
 
WBC 4.0 - 11.0 K/uL 6.2 
RBC 3.80 - 5.20 MIL/uL 4.69 
Hemoglobin 11.7 - 15.7 g/dL 13.1 
Hematocrit 35.0 - 47.0 % 37.8 
MCV 82.0 - 98.0 fL 80.7 
MCH 27.0 - 34.0 pg 26.9 
MCHC 32.0 - 36.0 g/dL 34.5 
RDW 11.5 - 14.5 % 14.8 
Platelet count 150 - 400 K/uL 237 
NEUT, %  40-74% 50.7 
LYM, %  14-46% 39.7 
MONO, %  4-13% 7.6 
EOS, %  0-7% 1.0 
BASO, %  0-3% 1.0 
NEUT, ABS 1.8 - 8.0 K/uL 3.14 
LYM, ABS 1.5 - 6.5 K/uL 2.46 
MONO, ABS 0 - 0.4 K/uL 0.47 
EOS, ABS 0 - 0.2 K/uL 0.06 




70-105mg/dL 70   
Renal Function     
BUN 5-20 mg/dL 13   
Creatinine, serum 0.5-0.8 mg/dL 0.76   
Electrolytes     
Chloride, Serum 96 - 108 mEq/L 101   
Calcium, Serum 8.8 - 10.8 mg/dL 10.0   
Sodium, serum 133 – 145 mEq/L 138   
Potassium, serum 3.3 - 5.1 mEq/L 4.5   
CO2 20-28 mEq/L 27   
 
 
Lipid Panel            
  
Cholesterol, Total <170 mg/dL 153 
Triglyceride, Ser/Plas <150 mg/dL 72 
HDL Cholesterol >40 mg/dL 73 
LDL (Calculated) <130 mg/dL 66 
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Cholesterol/HDL Ratio <5 ratio 2.1 
Non-HDL Chol, Calc <160 mg/dL 80 
LDL/HDL Ratio <3 ratio 0.9 






Troponin I       0.0-0.4mg/ml                                              0.32 
 
NT-proBNP                       <300 pg/mL                                539 
 
 
Cardiac MRI:  
 
Left Ventricle- Normal wall motion and systolic function. LVEF is 69%. There is mild 
apical hypertrophy present at apex with maximal wall thickness measuring 15mm at the 
anterior apical septum. No evidence of LV outflow tract obstruction.  
 
Right Ventricle- Normal wall motion, size, and function.  
 
Atria- Slight enlargement of left atrium with end diastolic diameter measuring 42mm 
(normal <40mm). Right atrium is unremarkable.  
 
Valves- Mild mitral valve regurgitation. Pulmonic, aortic, and tricuspid valves are 
unremarkable.  
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Quantitative Assessment:  
Right Ventricle:  
1. End diastolic volume, absolute: 148.6 mL; corrected (EDVI): 86.4  
mL/m^2. (normal 79.1±29.9ml) 
2. End systolic volume, absolute: 62.0 mL; corrected (ESVI): 36.1  
mL/m^2. (normal 32.6±19.7ml) 
3. Stroke volume, absolute: 86.6 mL; corrected (SVI): 50.4 mL/m^2. (normal 60-100mL) 
4. Cardiac output: 3.7 L/min; corrected (CI): 2.2 L/min/m^2. (normal 2.5-4.0 L/min/m^2) 
5. RV ejection fraction: 58.3%. (normal >49%) 
 
Left Ventricle:  
1. End diastolic volume, absolute: 150.4 mL; corrected (EDVI): 73.2  
mL/m^2. (normal <78 mL/m^2) 
2. End systolic volume, absolute: 46.3 mL; corrected (ESVI): 26.9  
mL/m^2. (normal 16-143mL) 
3. Stroke volume: 104.1 mL; corrected (SVI): 46.3 mL/m^2. (normal 33-47 mL/m^2) 
4. Cardiac output: 4.5 L/min; corrected (CI): 2.6 L/min/m^2. (normal 2.5-4.0 L/min/m^2) 
5. LV ejection fraction: 69.2%. (>56%) 
6. End diastolic mass: 152.0 g (normal range: 66-150g) 
 
All reference values come from MyHealth at Stanford - Test Results [Internet]. [cited 
2014 Apr 21].  
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Genetic Screening: 
Genetic screening of the sarcomere tested negative for any suggestive mutations.    
 
Diagnosis and Supporting Argument 
 Addie’s condition was presented with an abnormal EKG and several noted 
episodes of exercise-induced syncope within the past five years. A history of cardiac 
disorders is present in the paternal side, with both of Addie’s paternal grandparents 
having bypass surgery and her father presenting abnormal EKGs and mild left ventricular 
hypertrophy. The maternal family history has no known cardiac complaints. There is no 
history of early or sudden cardiac death. Review of Addie’s 12-lead EKG shows sinus 
rhythm with voltage criteria for left ventricular hypertrophy and increased QRS 
amplitude in V5, biphasic P waves, and deep anterolateral T wave inversion.  2-D 
echocardiography featured left ventricular hypertrophy with maximal wall thickness of 
1.5cm at the mid apical septum. Laboratory studies include an N-terminal proBNP 
abnormal level at 539 pg/ml. Cardiac magnetic resonance imaging confirmed left 
ventricular hypertrophy with normal wall motion and systolic function and no left 
ventricular outflow tract obstruction.  
Based on her abnormal EKG, propensity to syncope, and imaging of left 
ventricular hypertrophy, the differential diagnosis may include: apical hypertrophic 
cardiomyopathy (ApHCM), hypertrophic obstructive cardiomyopathy (HOCM), athletic 
heart syndrome, or aortic stenosis. Imaging techniques as well as cardiac catheterization 
presented no evidence of left ventricular outflow tract obstruction characteristic of 
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HOCM. Furthermore, no heart murmur associated with HOCM and aortic stenosis was 
detected upon physical examination, and maximal left ventricular wall thickness was 
measured at the mid apical septum rather than the more proximal end of the septum, 
which causes narrowing of the outflow tract (23). Cardiac magnetic resonance imaging 
revealed exaggerated thickening at the apex, which may be consistent with antero-lateral 
T wave inversion and reveal evidence of ApHCM rather than HOCM. Left ventricular 
hypertrophy in athletic heart syndrome can reach 14-16mm in wall thickness and is a 
potential diagnosis of Addie’s left ventricular hypertrophy given her participation in 
competitive athletics. However, echocardiographic assessment shows heterogeneous left 
ventricular hypertrophy particularly in the apical region and no enlarged left ventricular 
end-diastolic cavity common in athletic heart syndrome. These findings favor ApHCM 
over athletic heart syndrome (24). Aortic stenosis was ruled out based on assessment of 
aortic valve structure and pulmonary pressures measured by electrocardiography and 
cardiac magnetic resonance imaging. These image results yield no evidence of any 
narrowing of the aortic valve. Vasovagal syndrome might be considered as a possible 
factor causing syncope but does not account for the other abnormal cardiac findings and 
thus does not suffice as primary diagnoses. Diagnostic findings, mainly inverted T waves 
and left ventricular hypertrophy predominantly at the apex strongly suggest ApHCM as 
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Treatment 
Apical hypertrophic cardiomyopathy is not a curable disease and treatment is 
often a multidisciplinary approach aimed to promote heart relaxation and/or avoid 
abnormal heart rhythms depending on the symptoms presented. As Addie fails to present 
any angina or tachycardia, use of beta blockers to alleviate such symptoms was not 
considered. Based on AHA classifying guidelines for patients with HCM, Addie lacks 
most clearly defined risk factors such as outflow tract obstruction, ventricular wall 
thickness greater than 3cm, and family history of sudden cardiac death (25). Nonetheless, 
family history of left ventricular hypertrophy in her father as well as past episodes of 
syncope related with exertion are of concern. The implications of these concerns were 
discussed at length, including the recommendation for avoidance of high-intensity burst-
type activities as well as the utility of an implantable cardioverter defibrillator (ICD) for 
prevention of sudden cardiac death. The possibility of further review after 6 weeks of de-
training was offered as a diagnostic test to evaluate if there is any regression of Addie’s 
current cardiac hypertrophy. Addie agreed to undergo this complete de-training, as she is 
currently in the off-season for her collegiate sport. Screenings of all first-degree relatives 
both genetic and with echocardiograms and EKGs is advised. It was recommended that 
Addie’s two sisters be screened now and then on a once-yearly basis until the age of 18 
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Prognosis 
The most devastating complication of HCM is sudden cardiac death and usually 
occurs without warning largely in asymptomatic or mildly symptomatic young patients 
(26).  Apical hypertrophic cardiomyopathy is a relatively rare form of HCM that 
currently presents benign prognosis in terms of cardiac mortality. The risk of cardiac 
complications varies, and one third of ApHCM patients may develop potentially life-
threatening complications such as arrhythmias or stroke. However, roughly half of 
ApHCM patients remain asymptomatic and the long-term outcome for these people is 
generally good (27). As Addie presents minimal symptoms, she can expect to have a 
normal life expectancy free of any significant limiting symptoms.  
Follow up 
 Addie will return in approximately 6 weeks for evaluation and discussion of 
results of de-training. Further action will depend on results of this diagnostic test. In the 
case of regression, Addie’s diagnosis may be reconsidered to favor athletically-induced 
cardiac hypertrophy rather than ApHCM. Addie would continue on with her normal 
lifestyle yet with recommended avoidance of high-intensity burst-type activities, and she 
would receive annual clinical evaluations unless reoccurrence of symptoms should 
prompt re-evaluation.  
No regression will further support ApHCM as the diagnosis. Such case will 
warrant extensive discussion with Addie and her family regarding discontinuance of 
competitive sports, as intense physical exertion is linked to the risk of sudden cardiac 
death in patients with HCM. Lower risk activities within heart rate targets would be 
recommended.  ICD therapy and its life saving benefits as well as potential complications 
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would be discussed with Addie and her family and encouraged as a treatment in 
preventing sudden cardiac death.  
In either case, establishment with a cardiologist and annual clinical evaluations 
will be advised. Clinic and patient support networks to deal with the social and emotional 
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